eFFECTOR Therapeutics, Inc. (EFTR) Stock

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.

eFFECTOR Therapeutics, Inc. (EFTR) stock trades at $0.00 with a market capitalization of $2352. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, eFFECTOR Therapeutics, Inc. generates a return on equity (ROE) of 600.00% — well above the market average, a sign of a high-quality business, return on capital employed of 644.40%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: effector.com